NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
14 trialsNCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT06438627 2024-07-16
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT05798793 2024-04-02
NEOPCOSCC
Hospital of Stomatology, Wuhan University
Phase 3 Recruiting
NCT04830267 2024-03-28
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT05011227 2024-03-06
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting
NCT05069857 2023-11-22
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting
NCT05213884 2023-05-06
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Phase 2 Recruiting
NCT05097209 2023-03-23
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Recruiting
NCT05772208 2023-03-16
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Fudan University
Phase 3 Recruiting
NCT04826679 2021-04-01
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Sun Yat-sen University
Phase 2 Recruiting
NCT04453826 2020-09-28
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting